Chengying Xie

2.4k total citations
58 papers, 1.8k citations indexed

About

Chengying Xie is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Chengying Xie has authored 58 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 25 papers in Oncology and 10 papers in Hematology. Recurrent topics in Chengying Xie's work include Cancer Cells and Metastasis (6 papers), Protein Degradation and Inhibitors (6 papers) and Cancer therapeutics and mechanisms (5 papers). Chengying Xie is often cited by papers focused on Cancer Cells and Metastasis (6 papers), Protein Degradation and Inhibitors (6 papers) and Cancer therapeutics and mechanisms (5 papers). Chengying Xie collaborates with scholars based in China, United States and Ethiopia. Chengying Xie's co-authors include Liguang Lou, Haitian Quan, Yongping Xu, Fangfang Lü, Haiyi Guo, Jin Li, Shu Tian, Fu Li, Yun Li and Mingyue Zheng and has published in prestigious journals such as Journal of the American Chemical Society, PLoS ONE and Cancer Research.

In The Last Decade

Chengying Xie

55 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chengying Xie China 20 866 777 447 207 157 58 1.8k
Gianfranco De Feo Italy 5 728 0.8× 1.0k 1.3× 387 0.9× 225 1.1× 149 0.9× 9 1.8k
Maricla Galetti Italy 27 697 0.8× 653 0.8× 697 1.6× 196 0.9× 96 0.6× 53 1.6k
Bianca Maria Veneziani Italy 22 821 0.9× 1.0k 1.3× 689 1.5× 338 1.6× 167 1.1× 51 2.0k
Jie Zang China 25 593 0.7× 655 0.8× 477 1.1× 164 0.8× 77 0.5× 95 2.0k
Patricia Vrignaud France 25 945 1.1× 698 0.9× 305 0.7× 244 1.2× 158 1.0× 57 1.8k
Tomislav Dragovich United States 24 1.1k 1.3× 1.0k 1.4× 548 1.2× 444 2.1× 111 0.7× 80 2.3k
Edward Rosfjord United States 19 1.0k 1.2× 938 1.2× 383 0.9× 271 1.3× 64 0.4× 39 1.9k
Herman Burger Netherlands 28 1.3k 1.5× 1.2k 1.5× 330 0.7× 246 1.2× 83 0.5× 45 2.6k
Craig P. Carden United Kingdom 13 1.1k 1.3× 1.1k 1.4× 292 0.7× 413 2.0× 71 0.5× 18 2.1k
Dana T. Aftab United States 20 882 1.0× 803 1.0× 574 1.3× 417 2.0× 55 0.4× 45 1.8k

Countries citing papers authored by Chengying Xie

Since Specialization
Citations

This map shows the geographic impact of Chengying Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengying Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengying Xie more than expected).

Fields of papers citing papers by Chengying Xie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengying Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengying Xie. The network helps show where Chengying Xie may publish in the future.

Co-authorship network of co-authors of Chengying Xie

This figure shows the co-authorship network connecting the top 25 collaborators of Chengying Xie. A scholar is included among the top collaborators of Chengying Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengying Xie. Chengying Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Yujun, Yu Zhao, Wang Yf, et al.. (2025). Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemia. Acta Pharmacologica Sinica. 46(5). 1390–1403. 1 indexed citations
2.
Li, Wenjing, et al.. (2024). SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs. Acta Pharmacologica Sinica. 45(4). 857–866. 3 indexed citations
3.
Wu, Wenyong, Renhong Sun, Dingyan Wang, et al.. (2024). Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR–ABL–Positive Leukemia. Cancer Research. 85(1). 101–117. 4 indexed citations
4.
Mei, Lianghe, Ya‐Fang Wang, Chao Xu, et al.. (2023). Discovery, structural optimization, and anti-tumor bioactivity evaluations of betulinic acid derivatives as a new type of RORγ antagonists. European Journal of Medicinal Chemistry. 257. 115472–115472. 3 indexed citations
5.
Zhang, Jinfeng, Ziwei Luo, Kexin Yang, et al.. (2022). Dual-acting antitumor agents targeting the A2A adenosine receptor and histone deacetylases: Design and synthesis of 4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine derivatives. European Journal of Medicinal Chemistry. 236. 114326–114326. 11 indexed citations
6.
Yan, Wenzhong, Lijun Ling, Yiran Wu, et al.. (2021). Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents. Journal of Medicinal Chemistry. 64(22). 16573–16597. 21 indexed citations
7.
Zhu, Xi, Yuanzhen Suo, Yuting Fu, et al.. (2021). In vivo flow cytometry reveals a circadian rhythm of circulating tumor cells. Light Science & Applications. 10(1). 110–110. 56 indexed citations
8.
9.
Pang, Kai, Chengying Xie, Zhangru Yang, et al.. (2018). Monitoring circulating prostate cancer cells by in vivo flow cytometry assesses androgen deprivation therapy on metastasis. Cytometry Part A. 93(5). 517–524. 16 indexed citations
10.
Wang, Lei, Chengying Xie, Ye He, et al.. (2018). Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met.. PubMed. 8(8). 1541–1550. 6 indexed citations
11.
Zhong, Chenchun, Feng Chen, Junling Yang, et al.. (2018). Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species. Acta Pharmacologica Sinica. 39(6). 1048–1063. 56 indexed citations
12.
Zhu, Zhihui, Chenghua Lou, Zhiguo Zheng, et al.. (2017). ZFP403, a novel tumor suppressor, inhibits the proliferation and metastasis in ovarian cancer. Gynecologic Oncology. 147(2). 418–425. 13 indexed citations
13.
14.
15.
16.
Quan, Haitian, et al.. (2013). RON confers lapatinib resistance in HER2-positive breast cancer cells. Cancer Letters. 340(1). 43–50. 39 indexed citations
17.
Xie, Chengying, Yongping Xu, Wei Jin, & Liguang Lou. (2012). Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer. Anti-Cancer Drugs. 23(7). 698–705. 32 indexed citations
18.
Quan, Haitian, Chengying Xie, Yongping Xu, et al.. (2011). YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance. Cancer Letters. 314(1). 54–62. 12 indexed citations
19.
Tian, Shu, Haitian Quan, Chengying Xie, et al.. (2011). YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Science. 102(7). 1374–1380. 436 indexed citations
20.
Tian, Zhendong, et al.. (2009). Novel potato C2H2-type zinc finger protein gene, StZFP1, which responds to biotic and abiotic stress, plays a role in salt tolerance. Plant Biology. 12(5). 689–697. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gianfranco De Feo Breakdown of academic impact, for papers by Maricla Galetti Breakdown of academic impact, for papers by Bianca Maria Veneziani Breakdown of academic impact, for papers by Jie Zang Breakdown of academic impact, for papers by Patricia Vrignaud Breakdown of academic impact, for papers by Tomislav Dragovich Breakdown of academic impact, for papers by Edward Rosfjord Breakdown of academic impact, for papers by Herman Burger Breakdown of academic impact, for papers by Craig P. Carden Breakdown of academic impact, for papers by Dana T. Aftab
Rankless by CCL
2026